CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
‘Taco’ chance on the markets’ volatility, this is nacho average opportunity! Plus: Southwest, Boeing, Disney, Nvidia, Stellantis, McDonalds, Warner Brother
The Court of Appeals for the Federal Circuit on Thursday allowed the president to temporarily continue collecting the tariffs under the emergency powers law while he appeals the trade court’s decision.
Macy’s sales and profit slipped in its first quarter and the department store, citing more cautious customers and the impact that a trade war launched by the U.S., trimmed its profit forecast for 2025.
